N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
    2.
    发明授权
    N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases 有权
    细胞周期蛋白依赖性激酶N- [5 - [[[5-烷基-2-恶唑基]甲基]硫基] -2-噻唑基] - 甲酰胺抑制剂

    公开(公告)号:US06515004B1

    公开(公告)日:2003-02-04

    申请号:US09727957

    申请日:2000-12-01

    IPC分类号: C07D41712

    摘要: The present invention describes compounds of formula I: and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease.

    摘要翻译: 本发明描述了式I化合物及其对映异构体,非对映异构体及其药学上可接受的盐。式I化合物是蛋白激酶抑制剂,可用于治疗增殖性疾病,例如癌症,炎症和关节炎。 它们也可用于治疗阿尔茨海默病,化学疗法诱发的脱发和心血管疾病。

    Prostaglandin analogs
    3.
    发明授权
    Prostaglandin analogs 失效
    前列腺素类似物

    公开(公告)号:US5827868A

    公开(公告)日:1998-10-27

    申请号:US772830

    申请日:1991-10-07

    摘要: Thromboxane receptor antagonist activity is exhibited by compounds of the formula ##STR1## wherein: V is --(CH.sub.2).sub.m --, --O--, or ##STR2## but if V is --O--or ##STR3## R.sup.3 and R.sup.4 must complete an aromatic ring; W is --(CH.sub.2).sub.2 --, --CH.dbd.CH-- or phenylene; X is a single bond, --CH.dbd.CH--, --(CH.sub.2).sub.n --, or --O--(CH.sub.2).sub.n --; or X is branched alkylene or --O--branched alkylene wherein W is linked to Y through a chain n carbon atoms long; Y is --CO.sub.2 H, --CO.sub.2 alkyl, --CO.sub.2 alkali metal, --CH.sub.2 OH, --CONHSO.sub.2 R.sup.5, --CONHR.sup.6, or --CH.sub.2 -5-tetrazolyl; Z is O or NH; R.sup.3 and R.sup.4 are each independently hydrogen or alkyl or R.sup.3 and R.sup.4 together complete a ring optionally substituted through a ring carbon with a halo, lower alkyl, phenyl, halo (lower alkyl), halophenyl, oxo or hydroxyl group; and the remaining symbols are as defined in the specification.

    摘要翻译: 血栓烷受体拮抗剂活性由下式化合物显示:其中:V是 - (CH 2)m - ,-O-或,但是如果V是-O-或R 3,R 3和R 4必须完成 芳环; W是 - (CH 2)2 - , - CH = CH-或亚苯基; X是单键,-CH = CH - , - (CH 2)n - 或-O-(CH 2)n - 或X是支链亚烷基或-O-支链亚烷基,其中W通过链n个碳原子长连接到Y; Y是-CO 2 H,-CO 2烷基,-CO 2碱金属,-CH 2 OH,-CONHSO 2 R 5,-CONHR 6或-CH 2 5-四唑基; Z是O或NH; R 3和R 4各自独立地为氢或烷基,或者R 3和R 4一起形成任选被环碳取代的环,其中卤素,低级烷基,苯基,卤代(低级烷基),卤代苯基,氧代或羟基; 其余符号如说明书中所定义。

    Quinoline compounds and compositions thereof
    7.
    发明授权
    Quinoline compounds and compositions thereof 失效
    喹啉化合物及其组合物

    公开(公告)号:US4814454A

    公开(公告)日:1989-03-21

    申请号:US64716

    申请日:1987-06-22

    申请人: Raj N. Misra

    发明人: Raj N. Misra

    摘要: p-Aminophenols are provided having the structure ##STR1## wherein m is 0 to 5; X is CH or N; R.sup.1 and R.sup.2 may be the same or different and are H, lower alkyl, aryl, hydroxy, hydroxyalkyleneoxy, alkylthio, alkoxy, alkanoyloxy, aryloxy, halo, carboxy, alkoxycarbonyl or amido; R.sup.3 is H, lower alkyl, alkanoyl or aroyl; and R.sup.4 is H, lower alkyl or alkanoyl, and including acid-addition salts thereof, with the proviso that when X is CH, m is 0 and R.sup.1 is H, and when R.sup.4 is H, R.sup.2 is other than alkoxy, H or hydroxy, and when R.sup.4 is benzoyl, R.sup.2 is other than H.These compounds together with the compounds defined in the above proviso are useful as inhibitors of leukotriene production and as such are useful as antiallergy, anti-inflammatory and anti-psoriatic agents.

    摘要翻译: 提供具有结构的对氨基苯酚,其中m为0至5; X是CH或N; R 1和R 2可以相同或不同,为H,低级烷基,芳基,羟基,羟基亚烷基氧基,烷硫基,烷氧基,烷酰氧基,芳氧基,卤素,羧基,烷氧基羰基或酰胺基。 R3是H,低级烷基,烷酰基或芳酰基; 并且R4为H,低级烷基或烷酰基,并且包括其酸加成盐,条件是当X为CH时,m为0且R 1为H,当R 4为H时,R 2为烷氧基,H或羟基 ,当R 4为苯甲酰基时,R 2不是H.这些化合物与上述条件中定义的化合物一起用作白三烯生产的抑制剂,因此可用作抗炎,抗炎和抗牛皮癣药。

    Process for preparing azacycloalkanoylaminothiazoles
    9.
    发明授权
    Process for preparing azacycloalkanoylaminothiazoles 有权
    制备氮杂环烷酰氨基噻唑的方法

    公开(公告)号:US06639074B2

    公开(公告)日:2003-10-28

    申请号:US10100129

    申请日:2002-03-18

    IPC分类号: C07D47100

    摘要: The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R is alkyl, aryl or heteroaryl; R1, R2, R3, R4 and R5 are each independently hydrogen, alkyl, aryl or heteroaryl; R6 and R7 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; R8 is hydrogen, alkyl, aryl, heteroaryl, CONR9R10, COR11 or COOR12; R9, R10, R11 and R12 are each independently hydrogen, alkyl or aryl; m equals 0 to 5; and n equals 0 to 5, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula III′ and a 2-oxazolylalkyl derivative of formula IX.

    摘要翻译: 本发明涉及制备式I的5-(2-恶唑基烷硫基)-2-氮杂环烷酰氨基噻唑化合物或其药学上可接受的盐的新的,有效的方法,其中:R是烷基,芳基或杂芳基; R 1,R 2 R 3,R 4和R 5各自独立地为氢,烷基,芳基或杂芳基; R 6和R 7各自独立地为氢,烷基,芳基,杂芳基,卤素 ,羟基或烷氧基; R 8是氢,烷基,芳基,杂芳基,CONR 9 R 10,COR 11或COOR 12; R 9,R 10,R 11 且R 12各自独立地为氢,烷基或芳基; m等于0至5; 和等于0至5,这是细胞周期蛋白依赖性激酶(cdks)的新型有效抑制剂。 本发明还涉及新的关键中间体化合物,式III'的季铵盐和式IX的2-恶唑基烷基衍生物。